The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000677303
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
30/04/2026
Date registered
Help: Date registered
5/06/2026
Date last updated
Help: Date last updated
2/10/2026
Date data sharing statement initially provided
Help: Data sharing statement date
5/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Ischaemic changes in the retina of patient with diabetic macular oedema with the use of aflibercept 8mg dose
Scientific title
Investigating the impact of intravitreal aflibercept 8mg on retinal ischaemia in diabetic macular oedema: a prospective imaging study
Additional trial identifiers [1] 317143 0
Nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
diabetic macular oedema (DMO) 341720 0
Condition category
Condition code
Eye 337798 337798 0 0
Diseases / disorders of the eye
Metabolic and Endocrine 338011 338011 0 0
Diabetes

Intervention/exposure
Study type
Observational
Patient registry
True
Target follow-up duration
6
Target follow-up type
Months
Description of the intervention or exposure
We would be enrolling patients who would have gotten 8mg Aflibercept regardless of participation in the study. Aflibercept 8mg as a part of standard of care in the hospital

Drug: Aflibercept
Dose: 8mg
Duration: Monthly injections for 6 months
Mode of Delivery: Intravitreal injection administered by an ophthalmologist
Adherence: monthly appointments booked with the patient for administration of the injection. Duration of each of each of these appointments will be under 2 hours,

Imaging schedule:
First visit and final visit (6 months from the first visit) - Ultra-widefield (UWF) Optical Coherence Tomography (OCT) fluorescein angiography (FA), Ultra-widefield Optical Coherence Tomography (UWF-OCT), spectral-domain OCT (SD-OCT), Optical Coherence Tomography Angiography (OCT-A) macula, Ultra-widefield fundus imaging

Monthly visits - UWF OCT, OCT macula, Ultra-widefield fundus imaging.

fluorescein dye is only used in the first and the final visit.

Duration: The imaging would take up to 2 hours.
Intervention code [1] 333911 0
Not applicable
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345263 0
To quantify the mean change in total retinal non-perfusion area (NPA) from baseline to month 6 in eyes with diabetic macular oedema (DMO) receiving monthly intravitreal aflibercept 8mg as part of the standard-of-care
Timepoint [1] 345263 0
NPA at baseline is compared to NPA at Month 6 post-treatment commencement.
Secondary outcome [1] 461134 0
Quantify changes in macular ischaemia
Timepoint [1] 461134 0
baseline and month 6 post the commencement of the treatment
Secondary outcome [2] 461135 0
Determine the proportion of eyes with greater than or equal to 10% increase or greater than or equal to 10% decrease in total retinal non-perfusion area (NPA) at Month 6 (from the commencement of the treatment) as measured using ultrawide field OCTA
Timepoint [2] 461135 0
baseline and 6 month post-commencement of the treatment
Secondary outcome [3] 461137 0
changes in non-perfusion area (NPA)/macular perfusion
Timepoint [3] 461137 0
UWF-FA is done at baseline and 6 month visit (6 month post commencement of the treatment)
Secondary outcome [4] 461652 0
Macular damage
Timepoint [4] 461652 0
OCT is performed on all monthly visits
Secondary outcome [5] 462077 0
Best Corrected Visual Acuity (BCVA)
Timepoint [5] 462077 0
BCVA is assessed on all monthly visits

Eligibility
Key inclusion criteria
•Adults (greater than or equal to 18 years) with type 1 or type 2 diabetes. Centre-involving DMO requiring anti-Vascular Endothelial Growth Factor (anti-VEGF) therapy.
• Best-corrected visual acuity (BCVA) 20/25–20/320 (ETDRS).
• Able and willing to consent for the study, complete all required imaging and follow-up visits.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
• Pregnant or breastfeeding women, or women planning pregnancy during the study period or within 3 months after the last aflibercept 8 mg injection, because the safety of intravitreal anti-VEGF agents in pregnancy is uncertain and these drugs can reduce circulating VEGF, which is important for fetal development (10). If a participant becomes pregnant or is found to be pregnant during the study, study treatment with intravitreal aflibercept will be stopped as soon as pregnancy is identified, and the participant will be withdrawn from the interventional component of the study.
• Prior intraocular surgery or pan-retinal photocoagulation (PRP) within 3 months of baseline.
• Active proliferative diabetic retinopathy (PDR) requiring immediate PRP.
• Macular ischaemia due to causes other than diabetic retinopathy.
• Significant media opacity precluding quality imaging.
• Uncontrolled glaucoma – confirmed decline in visual function over time even after starting on >2 IOP lowering medication.
• Any other cause of retinal vascular disease such as retinal vein occlusion.
• Previous treatment for DMO within 6 months of screening visit including intravitreal anti-VEGF/corticosteroids or macular laser.

Study design
Purpose
Duration
Longitudinal
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 29465 0
Lions Eye Institute Day Surgery Centre - Nedlands
Recruitment hospital [2] 29466 0
Sir Charles Gairdner Hospital - Nedlands
Recruitment postcode(s) [1] 45783 0
6009 - Nedlands

Funding & Sponsors
Funding source category [1] 321727 0
Commercial sector/Industry
Name [1] 321727 0
Bayer Health Care Pharmaceuticals
Country [1] 321727 0
Australia
Primary sponsor type
Individual
Name
Prof. Chandra Balaratnasingam, Lions Eye Institute
Address
Country
Australia
Secondary sponsor category [1] 324583 0
None
Name [1] 324583 0
Address [1] 324583 0
Country [1] 324583 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320260 0
The University of Western Australia Human Research Ethics Committee
Ethics committee address [1] 320260 0
Ethics committee country [1] 320260 0
Australia
Date submitted for ethics approval [1] 320260 0
20/04/2026
Approval date [1] 320260 0
05/06/2026
Ethics approval number [1] 320260 0
2026/ET000188
Ethics committee name [2] 320288 0
WA Health Central HREC
Ethics committee address [2] 320288 0
Ethics committee country [2] 320288 0
Australia
Date submitted for ethics approval [2] 320288 0
10/06/2026
Approval date [2] 320288 0
Ethics approval number [2] 320288 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149922 0
Prof Chandra Balaratnasingam
Address 149922 0
Lions Eye Institute, 2 Verdun St, Nedlands, Western Australia. 6009
Country 149922 0
Australia
Phone 149922 0
+61477713932
Fax 149922 0
Email 149922 0
Contact person for public queries
Name 149923 0
Chandra Balaratnasingam
Address 149923 0
Lions Eye Institute, 2 Verdun St, Nedlands, Western Australia 6009
Country 149923 0
Australia
Phone 149923 0
+61477713932
Fax 149923 0
Email 149923 0
Contact person for scientific queries
Name 149924 0
Prof. Chandra Balaratnasingam
Address 149924 0
Lions Eye Institute, 2 Verdun St, Nedlands, Western Australia. 6009
Country 149924 0
Australia
Phone 149924 0
+61477713932
Fax 149924 0
Email 149924 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Informed consent form    2026_ET000188_v1_01 - PICF + withdrawal form revised.pdf


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.